Breaking News, Collaborations & Alliances

Orion, Bayer Enter Global Development Pact

To develop and commercialize ODM-201 to treat prostate cancer

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Orion Corp. and Bayer have entered a global partnership for the development and commercialization of ODM-201, an investigational oral androgen receptor inhibitor entering Phase III development for the treatment of prostate cancer.   The companies will jointly develop ODM-201, with Bayer covering the majority of development costs and responsibility for global commercialization. Orion has the option to co-promote ODM-201 in Europe and will manufacture the product. Orion will receive €50 million up...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters